title: Menogaril in the treatment of relapsed multiple myeloma. A phase II trial of the Cancer Center of Wake Forest University.
abstract: Fifteen patients with relapsed multiple myeloma (MM) were treated with menogaril 160 mg/m2 intravenously (IV) every 28 days. No responses were seen: 8 patients had stable disease, 4 progressed after one course of therapy, and 3 patients were removed from study after 1 course for other reasons. Four of the 8 patients with stable disease had an improved performance status, and 3 had a decrease in analgesic use. The major toxicity was myelosuppression. The median progression-free interval was 3.0 months with a range of 0.7 to 22 months and median survival was 11.3 months with a range of 0.7 to 39+ months. Menogaril displays little activity in patients with previously treated MM.
authors.affiliation: Comprehensive Cancer Center of Wake Forest University, Winston-Salem, NC.
authors.forename: J M
authors.initials: JM
authors.lastname: Cruz
authors.forename: L D
authors.initials: LD
authors.lastname: Case
authors.forename: H B
authors.initials: HB
authors.lastname: Dalton
authors.forename: W L
authors.initials: WL
authors.lastname: Ramseur
authors.forename: F
authors.initials: F
authors.lastname: Richards
authors.forename: D V
authors.initials: DV
authors.lastname: Jackson
authors.forename: H B
authors.initials: HB
authors.lastname: Muss
authors.forename: P J
authors.initials: PJ
authors.lastname: Zekan
authors.forename: R A
authors.initials: RA
authors.lastname: Brodkin
authors.forename: R C
authors.initials: RC
authors.lastname: Brown
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D006801:Humans; D017290:Menogaril; D009101:Multiple Myeloma / Q000188:drug therapy*; D009621:Nogalamycin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D017290:Menogaril; D009621:Nogalamycin